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For personal usSummary Background: Little is known about the preoperative predictive factors that could
identify subsets of favorable patients who can be possibly curedwith robot-assisted radical pros-
tatectomy (RARP) alone in locally advanced prostate cancer (LAPCa). Our study was designed to
identify clinical predictors of pathologic organ-confined disease (pOCD) in RARP setting.
Methods: Between 2007 and 2013, clinicopathological and oncological data from 273 consecu-
tive men undergoing robot-assisted RP with extended PLND for clinically LAPCa were reviewed
in a single-institution, retrospectively. After exclusion of patients who received neoadjuvant
hormone treatment before surgery, 186 subjects satisfied the final inclusion criteria.
Results: Fourty-three patients (23.1% of total cohort) with preoperative clinically LAPCa pa-
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For personallevel, preoperative PSAD, positive core percent, maximal tumor volume in any core, and biopsy
Gleason score were significantly associated with down-staging into pOCD following RARP. Multi-
variate logistic regression analysis revealed that lower preoperative PSA (10 ng/mL) and
maximal tumor volume in any core (70%) were independent predictors of pOCD following RARP.
Conclusions: Approximately 23% of preoperative clinically LAPCa patients were down-staged to
pOCD following RARP. Preoperative PSA and maximal tumor volume in any biopsy core might be
useful clinical predictors of pOCD in clinically LAPCa patients in RARP setting.
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Despite the widespread application of prostate-specific
antigen (PSA)-based screening leading to a profound stage
migration in prostate cancer (PCa), as many as one-third of
PCa cases have a high-risk feature that requires aggressive
treatment.1e3 Until recently, surgical treatment has not
been commonly used to treat locally-advanced PCa
(LAPCa).4 Optimal disease management in these patients
remains challenging, and strong advocates propose various
treatment options, such as radical prostatectomy (RP),
radiotherapy (RT), androgen deprivation therapy, and
increasingly, a multimodal approach.5 Surgery offers an
attractive opportunity for tumor excision, either as defini-
tive management or as a first step in multimodal therapy.6
Surgery can also identify a substantial subset of men with
favorable clinical features in whom additional therapy is
not indicated.1,7 Approximately 20%e30% of men undergo-
ing RP for clinical stage T3 PCa have pathological organ-
confined disease (pOCD).8,9 A study conducted at Memo-
rial Sloan-Kettering Center followed 176 men with cT3 over
a 20-year period. Within this cohort, only 64 patients
received neoadjuvant hormone therapy (HT), and more
than one-half (52%) of patients remained free of disease
recurrence following RP at a mean follow-up time of 6.4
years.8 During the last several years, an increased number
of publications have discussed the use of minimally invasive
techniques, particularly robot-assisted radical prostatec-
tomy (RARP), in high-risk or locally-advanced PCa patients.
Numerous studies noted that RARP demonstrated similar
oncological outcomes to open surgery and other minimally
invasive surgeries in this clinical scenario.10e13 Although
recent published data illustrate of the therapeutic poten-
tial and technical feasibility of RARP in LAPCa patients,
little is known about preoperative predictive factors that
can identify subsets of favorable patients who may benefit
from RARP monotherapy without any further treatment.
This retrospective study was designed to evaluate these
predictive factors with respect to down-staging to pOCD in
clinically LAPCa cases following RARP.
2. Materials and methods
2.1. Study population and data collection
We retrospectively reviewed the data of 1138 PCa patients
who underwent extraperitoneal RARP performed by a singleUser (n/a) at KESLI - Yonsei University M
 use only. No other uses without permissionsurgeon at Severance Hospital between January 2007 and
December 2013. Of these men, 273 consecutive LAPCa
cases (stages cT3-4) with no lymph node or distant metas-
tasis (cT3-4N0M0) were identified. After excluding 70 pa-
tients who received neoadjuvant treatment before surgery
and 17 patients whose lymph node metastasis was not
verified by pathology, 186 men undergoing robot-assisted
RP with extended PLND satisfied the final inclusion criteria.
Preoperative characteristics, including age, body mass
index, clinical stage, PSA, and prostate biopsy findings
(Gleason grade, positive core percent, and maximal tumor
volume in any biopsy core) were collected from electronic
medical records. In most cases, TRUS-guided biopsy con-
sisted of a minimum of 10 cores including a 2-core transi-
tion zone biopsy. Positive core percent were calculated
using formulas: number of positive cores/total number of
biopsy core. The clinical stages of all the prostate cancer
patients included in this study were determined by 3.0T MRI
system staging, and the upper normal limit for pelvic
lymphadenopathy by prostate MRI was 5 mm.
The RARP and bilateral pelvic lymph node dissections
(PLND) were carried out using our standardized extraper-
itoneal technique and protocol.14 The indication for and
use of a unilateral or bilateral nerve-sparing technique
depended on individual patient characteristics. Clinical
staging was assigned by the attending urologist according to
the 2002 TNM system. Biopsy and pathological grading were
performed according to the Gleason grading system, and
Gleason scores were assigned by genitourinary pathologists.
2.2. Good clinical practice protocols
The study was carried out in agreement with the applicable
laws and regulations, good clinical practices, and ethical
principles as described in the Declaration of Helsinki. The
institutional review board of the hospital approved the
study protocol (Approval number: 4-2014-0619).
2.3. Statistical analysis
Continuous variable values are presented as the median
and interquartile range (IQR). Differences in variables with
a continuous distribution across dichotomous categories
were assessed using the ManneWhitney U test. The Fisher
exact or Chi-square tests were used to evaluate the asso-
ciation between categorical variables. We used univariate
and multivariate logistic regression analysis to determine
predictive variables of pOCD in 158 patients, excludingedical College from ClinicalKey.com by Elsevier on March 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 1 Clinicopathologic characteristics of study
patients.
Variables Value
Patients, n 186
Follow-up period, months
(median, IQR)
34.1 (21.5e45.1)
Preoperative variables
Age at operation, years
(mean, IQR)
68.0 (62.0e72.0)
BMI, kg/m2 (median, IQR) 24.1 (22.0e25.4)
PSA, ng/mL (median, IQR) 10.87 (5.78e18.98)
PSAD, ng/mL/cm3 (median, IQR) 0.33 (0.19e0.73)
Positive core percent
(median, IQR)
33.3 (16.7e54.4)
Maximal tumor volume in any
core (median, IQR)
60.0 (30.0e80.0)
Gleason biopsy score, n (%)
6 54 (29.0)
7 (3 þ 4) 41 (22.0)
7 (4 þ 3) 30 (16.1)
8 56 (30.1)
9 5 (2.7)
Clinical T stage, n (%)
T3a 139 (74.7)
T3b 38 (20.4)
T4 9 (4.8)
Postoperative pathological variables
High-grade PIN 82 (44.1)
Lymphovascular invasion 15 (8.1)
Pathologic Gleason score
6 31 (16.7)
7 (3 þ 4) 57 (30.6)
7 (4 þ 3) 49 (26.3)
8 20 (10.8)
9 29 (15.6)
Pathologic T stage
T2a 16 (8.6)
T2b 0 (0.0)
T2c 27 (14.5)
T3a 108 (58.1)
T3b 30 (16.1)
T4 5 (2.7)
Pathologic N stage
N0 182 (97.8)
N1 4 (2.2)
Positive surgical margin 64 (34.4)
BMI, body mass index; IQR, interquartile range; PSA, prostate-
specific antigen; PSAD, prostate-specific antigen density; PIN,
prostatic intraepithelial neoplasia.
122 H.W. Kang et al.those lacking prostate biopsy parameters. Variables
yielding P < 0.2 after univariate analysis were included in
the multivariate analysis. Receivers operating character-
istic (ROC) curves were constructed to obtain the cut-off
values of PSA, Gleason biopsy grade, positive biopsy core
percent, and maximal tumor volume in any biopsy core that
would confer optimal sensitivity and specificity for pre-
dicting the pOCD of prostatectomy specimens. Statistical
significance was indicated if P < 0.05, and all reported P-
values are 2-sided. Statistical analyses were performed
using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA).
3. Results
Table 1 lists the baseline characteristics and pathologic
results of the 186 patients with clinically LAPCa. Median
pre-biopsy PSA and PSA density (PSAD) levels were
10.87 ng/mL (IQR: 5.78e18.98) and 0.33 ng/mL/g (IQR:
0.19e0.73), respectively. Clinical stages included cT3a in
139 (74.7%), cT3b in 38 (20.4%), and cT4 in 9 (4.8%)
patients.
After RARP, pathological Gleason scores were identical
in 82 patients (44.1%). Compared to the biopsy-based
Gleason score, pathologic over-grading and under-grading
occurred in 66 (35.5%) and 38 (20.4%) patients, respec-
tively. LN invasions and positive surgical margins (PSMs)
were found in only 4 patients (2.2%) and in 64 (34.4%) pa-
tients, respectively.
3.1. Prediction of pOCD in clinically LAPCa patients
after RARP
After RARP, 43 patients (23.1% of total cohort) with pre-
operative clinically LAPCa patients were down-staged to
pOCD following RARP. PSMs were found in 6 (14.0%) of pOCD
and 58 (40.6%) of pathologically LAPCa (P Z 0.001). Pre-
operative serum PSA (P < 0.001), preoperative PSAD
(P < 0.001), positive core percent (P Z 0.019), maximal
tumor volume in any core (P Z 0.005), and biopsy Gleason
score (P Z 0.002) were significantly associated with down-
staging into pOCD after RARP (Table 2). The area under the
curve (AUC) for the discriminative ability of pOCD in clini-
cally LAPCa patients was 0.680 for preoperative PSA and
0.617 and 0.641 for positive core percent and maximal
tumor volume in any core, respectively (P < 0.05 for each
variable). After grouping Gleason biopsy scores into five
categories (6, 7 with primary Gleason pattern 3, 7 with
primary Gleason pattern 4, 8, and 9), the AUC of biopsy
Gleason score related to the discriminative ability of pOCD
in clinically LAPCa was 0.647 (P Z 0.004).
Table 3 shows results from univariate and multivariate
logistic regression analyses used to predict pOCD in clini-
cally LAPCa after RARP. The cut-off values conferring
optimal sensitivity and specificity for the discriminative
ability of pOCD in LAPCa patients using ROC curve were PSA
at 10 ng/mL, positive core percent at 33.3%, maximal
tumor volume in any core at 70%, and biopsy Gleason score
at 7 with primary Gleason pattern 3. In univariate analyses,
preoperative PSA level (10 ng/mL), positive core percent
(33.3%), Maximal tumor volume in any core (70%), and
biopsy Gleason score (7 with primary Gleason pattern 3)Downloaded for Anonymous User (n/a) at KESLI - Yonsei University Med
For personal use only. No other uses without permission. Cwere associated with pOCD. Multivariate analysis revealed
that lower preoperative PSA (10 ng/mL) and maximal
tumor volume in any core (70%) were independent pre-
dictors of pOCD following RARP.
4. Discussion
The optimal treatment regimen for men with LAPCa is
controversial. At this stage the tumors appears to extendical College from ClinicalKey.com by Elsevier on March 06, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 2 Comparison of preoperative variables between pathologically organ-confined and non-organ confined groups after
robot-assisted radical prostatectomy in patients with clinically locally-advanced prostate cancer.
Variables Final pathology P
Organ-confined Non-organ confined
Patients, n (%) 43 (23.1) 143 (76.9)
Preoperative variables
Age at operation, years (mean, IQR) 67.0 (61.0e71.0) 68.0 (62.0e72.0) 0.519*
BMI, kg/m2 (median, IQR) 24.2 (21.5e26.1) 24.0 (22.3e25.4) 0.991*
PSA, ng/mL (median, IQR) 6.00 (4.92e11.70) 12.23 (6.91e20.93) <0.001*
PSAD, ng/mL/cm3 (median, IQR) 0.20 (0.12e0.33) 0.38 (0.23e0.78) <0.001*
Positive core percent (median, IQR) 23.5 (8.3e41.7) 37.5 (16.7e58.3) 0.019*
Maximal tumor volume in any core (median, IQR) 40.0 (20.0e70.0) 70 (30.0e90.0) 0.005*
Biopsy Gleason score, n (%) 0.002y
6 22 (51.2) 32 (22.4)
7 (3 þ 4) 6 (14.0) 35 (24.5)
7 (4 þ 3) 7 (16.3) 23 (16.1)
8 6 (14.0) 50 (35.0)
9 2 (4.7) 3 (2.1)
Clinical T stage, n (%) 0.464y
T3a 35 (81.4) 104 (72.7)
T3b 7 (16.3) 31 (21.7)
T4 1 (2.3) 8 (5.6)
IQR, interquartile range; BMI, body mass index; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; P-values were
obtained from the *ManneWhitney U test or yFisher’s exact test.
Robot prostatectomy for LAPCa 123beyond the prostatic capsule with invasion into the peri-
capsular tissue, apex, bladder neck, or seminal vesicle but
is not associated with lymph node involvement or distant
metastases.15,16 Until recently, surgical management was
often disregarded in these individuals due to their
increased risk of BCR, systemic progression, and worsening
oncologic outcomes.17e19 However, several recent studies
related to high-risk PCa have presented alternative
views.7,20e22 In a Mayo Clinic study of men undergoing RP,
cT3 was found in 841 (15%) of the 5662 patients. Of the cT3
patients, 661 (79%) men did not receive neoadjuvant HT.
After a pathological review of these patients, 223 (27%) hadTable 3 Prediction of organ-confined disease after robot-assis
advanced prostate cancer.
Parameters Univari
OR (95%, CI)
Age (continuous) 0.991 (0.945e1.
BMI (continuous) 0.957 (0.851e1.
PSA (<10 ng/mL) 3.898 (1.849e8.
Positive core percent (33.3%) 2.620 (1.247e5.
Maximal tumor volume in any core (70%) 5.338 (1.983e14
Biopsy GS (7 with primary Gleason
pattern 3)
2.117 (1.043e4.
Clinical T stage
T3a e
T3b 0.671 (0.271e1.
T4 0.371 (0.045e3.
OR, odds ratio; CI, confidence interval; BMI, body mass index; PSA, p
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prevalence of clinical over-staging.23 Moreover, Tai
et al reported that even patients with pathological T3 or
higher stages, there are still optimistically high chances of
3-year recurrence-free survival at 81.1% (pT3a), and 62.6%
(pT3b-4), and concluded that radical prostatectomy is
curative even for some locally advanced prostate cancers in
a midterm follow-up.24 In our cohort, approximately 22% of
preoperative clinically LAPCa patients were down-staged to
pOCD following RARP. However, according to the Surveil-
lance, Epidemiology, and End Results data, only 6% of men
with locally advanced, nonmetastatic disease are treatedted radical prostatectomy in patients with clinically locally-
ate analysis Multivariate analysis
P OR (95%, CI) P
040) 0.722
077) 0.468
216) <0.001 2.670 (1.194e5.969) 0.017
505) 0.011 1.060 (0.442e2.542) 0.896
.367) 0.001 3.837 (1.296e11.354) 0.015
298) 0.038 1.631 (0.761e3.496) 0.209
659) 0.388
075) 0.358
rostate-specific antigen; GS, Gleason score.
edical College from ClinicalKey.com by Elsevier on March 06, 2019.
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124 H.W. Kang et al.surgically. Even among the youngest patients, only 19% are
treated with radical prostatectomy. In the context of such
significant clinical challenges, pretreatment prediction
model which can help guide decision making is essential for
appropriate management in men with LAPCa. Concentrated
efforts of several research groups has been developed a
nomogram based on clinical stage, Gleason’s score of the
prostate needle biopsy, and serum PSA to assist physicians
in making clinical recommendations for men with clinically
localized PCa. On the contrary, this issue has not been
sufficiently addressed in LAPCa. Recently, Joniau
et al analyzed single center data for 200 patients with
clinically unilateral T3a PCa underwent a radical prosta-
tectomy (RP).25 The authors presented a table combining
preoperative serum PSA and biopsy GS to predict histo-
pathologic results in clinically unilateral T3a PCa. And then,
this table was successfully validated in multicenter retro-
spective cohort.26 We evaluated preoperative predictive
factors, such as PSA levels, positive core/total biopsy core
percent, maximum cancer involvement in positive cores,
and biopsy Gleason score, that can identify subsets of
favorable pathologic outcomes in RARP setting. To the best
of our knowledge, no previous RARP series has reported a
preoperative predictive factors for predicting pathologic
outcome after RARP in LAPCa. Our results indicated that
lower preoperative PSA (10 ng/mL) and maximal tumor
volume in any core (70%) were independent predictors of
pOCD following RARP. When patients with LAPCa are well
selected, RARP can offer an attractive opportunity for
complete tumor excision without any further treatment.
This study has several potential limitations. First, its
retrospective design may produce some sampling bias. Also,
the study included data from patients treated at a single
tertiary institution by one surgeon, the time frame of which
encompassed the surgical learning curve and development
of the robot technology. Another concern relates to missing
biopsy variables from some patients, further decreasing the
size of our cohort. Notwithstanding the limitations, this
study identified relevant clinical evidence supporting the
role of RARP in LAPCa patients for whom surgical inter-
vention had been previously abandoned due to potentially
over-staged based on clinical staging.
In conclusion, clinically LAPCa is still frequently over-
staged based on pre-treatment clinical staging criteria.
Preoperative variables, including PSA levels and maximum
cancer involvement in positive cores might identify subsets
of favorable patients who can be possibly cured with robot-
assisted radical prostatectomy (RARP) alone in clinically
LAPCa.
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